Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis is a research paper published in Frontiers in Oncology (2021). On theSindex it has a DataRank of 0. It has been cited 76 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Cancer Prevention and Research Institute of Texas
Grant: RR200009
National Institutes of Health
Grant: 1K22CA241113-01, 5K22 CA207463
Susan G. Komen
Grant: CCR18548284
NCI NIH HHS
Grant: K22 CA241113
NCI NIH HHS
Grant: K22 CA207463
National Institutes of Health
Grant: 5K22CA207463-03
Wnt pathway dynamics in breast cancer metastasis
National Institutes of Health
Grant: 1K22CA241113-01
Characterizing and targeting intra-tumor heterogeneity in triple negative breast cancer chemoresistance and multi-organ metastasis
FWCI
4.95
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 12 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 12 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 11 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 11 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 10 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 10 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 9 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 9 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 8 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 8 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 6 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 6 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 5 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 5 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 1 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 1 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 2 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 2 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 3 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis
Additional file 3 of EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis